A further study is recruiting to assess the combination of ARV-471 and everolimus, an mTOR inhibitor, in patients with advanced or metastatic ER+/HER2- breast cancer who have received a prior CDK4/6 inhibitor and endocrine therapy in the advanced/metastatic setting (NCT05501769). Here, ESR1 is linked to breast carcinoma.